These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 24985716)

  • 1. Vedolizumab: first global approval.
    Poole RM
    Drugs; 2014 Jul; 74(11):1293-303. PubMed ID: 24985716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
    Cohen RD; Bhayat F; Blake A; Travis S
    J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
    Hinojosa Del Val J; Barreiro-de Acosta M
    Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.
    Yajnik V; Khan N; Dubinsky M; Axler J; James A; Abhyankar B; Lasch K
    Adv Ther; 2017 Feb; 34(2):542-559. PubMed ID: 28070861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
    Garnock-Jones KP
    BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vedolizumab for the treatment of ulcerative colitis.
    Shahidi N; Bressler B; Panaccione R
    Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
    Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
    Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
    Boden EK; Shows DM; Chiorean MV; Lord JD
    Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
    Hagan M; Cross RK
    Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing.
    D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
    Immunotherapy; 2019 May; 11(7):565-575. PubMed ID: 30860423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
    Scribano ML
    World J Gastroenterol; 2018 Jun; 24(23):2457-2467. PubMed ID: 29930467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary Manifestation of Crohn's Disease Developed Under Treatment With Vedolizumab.
    Lissner D; Glauben R; Allers K; Sonnenberg E; Loddenkemper C; Schneider T; Siegmund B
    Am J Gastroenterol; 2018 Jan; 113(1):146-148. PubMed ID: 29311733
    [No Abstract]   [Full Text] [Related]  

  • 17. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
    Wyant T; Fedyk E; Abhyankar B
    J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
    J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
    Battat R; Ma C; Jairath V; Khanna R; Feagan BG
    Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of vedolizumab for ulcerative colitis and Crohn's disease.
    Colombel JF; Sands BE; Rutgeerts P; Sandborn W; Danese S; D'Haens G; Panaccione R; Loftus EV; Sankoh S; Fox I; Parikh A; Milch C; Abhyankar B; Feagan BG
    Gut; 2017 May; 66(5):839-851. PubMed ID: 26893500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.